CN1931292A - 一种治疗泌尿系疾病的药物及质量控制方法 - Google Patents
一种治疗泌尿系疾病的药物及质量控制方法 Download PDFInfo
- Publication number
- CN1931292A CN1931292A CNA200610048680XA CN200610048680A CN1931292A CN 1931292 A CN1931292 A CN 1931292A CN A200610048680X A CNA200610048680X A CN A200610048680XA CN 200610048680 A CN200610048680 A CN 200610048680A CN 1931292 A CN1931292 A CN 1931292A
- Authority
- CN
- China
- Prior art keywords
- solution
- water
- test
- chromatograph
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 238000003908 quality control method Methods 0.000 title claims abstract description 8
- 208000014001 urinary system disease Diseases 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title claims description 19
- 239000000463 material Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 238000012360 testing method Methods 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 239000000047 product Substances 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 21
- 239000013558 reference substance Substances 0.000 claims description 21
- 229960004756 ethanol Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 10
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 10
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 10
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 10
- 229940074393 chlorogenic acid Drugs 0.000 claims description 10
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 10
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 10
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- 241000218176 Corydalis Species 0.000 claims description 8
- 229960000583 acetic acid Drugs 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 230000003760 hair shine Effects 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 208000012931 Urologic disease Diseases 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 238000011003 system suitability test Methods 0.000 claims description 3
- 239000012085 test solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 208000009911 Urinary Calculi Diseases 0.000 abstract description 15
- 206010007027 Calculus urinary Diseases 0.000 abstract description 12
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 208000019206 urinary tract infection Diseases 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 201000007094 prostatitis Diseases 0.000 abstract description 3
- 230000027939 micturition Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000522190 Desmodium Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000004317 gizzard Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 63
- 241000700159 Rattus Species 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 239000013641 positive control Substances 0.000 description 10
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 241000588769 Proteus <enterobacteria> Species 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 230000035619 diuresis Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000010603 pastilles Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 210000004303 peritoneum Anatomy 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229930189907 rotundine Natural products 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000000913 Kidney Calculi Diseases 0.000 description 4
- 206010029148 Nephrolithiasis Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011169 microbiological contamination Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010006987 Calculus bladder Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 201000000210 bladder calculus Diseases 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000000387 litholytic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 3
- 229960001180 norfloxacin Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 206010060976 Bacillus infection Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ACBZLBZXXKRDPH-UHFFFAOYSA-N azanium;ethane-1,2-diol;chloride Chemical compound [NH4+].[Cl-].OCCO ACBZLBZXXKRDPH-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000002504 lithotomy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940095453 prednisone 10 mg Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量 | 病理检查肾结石程度 | 肉眼检查肾脏外观 | |||||||
(/kg) | - | + | ++ | +++ | P值 | 正常 | 灰褐色 | 灰白色及水肿 | P值 |
受试药物 | 1.60g | 2 | 3 | 3 | 2 | >0.05 | 4 | 5 | 1 | <0.05 |
受试药物 | 0.80g | 0 | 1 | 9 | 0 | >0.05 | 3 | 4 | 3 | >0.05 |
受试药物 | 0.40g | 0 | 0 | 9 | 1 | >0.05 | 3 | 3 | 4 | >0.05 |
结石通 | 10g | 1 | 2 | 2 | 5 | >0.05 | 3 | 4 | 3 | <0.05 |
模型对照 | 20ml | 0 | 0 | 5 | 5 | 0 | 2 | 8 | ||
正常对照 | 20ml | 10 | 0 | 0 | 0 | <0.01 | 10 | 0 | 0 | <0.01 |
组别 | 剂量(/kg) | N | 结石重量(mg, X±S) |
受试药物 | 1.60g | 9 | 1.69±0.51* |
受试药物 | 0.80g | 10 | 2.01±1.30 |
受试药物 | 0.40g | 10 | 1.97±0.65 |
结石通 | 10g | 10 | 1.72±0.73 |
常水 | 10ml | 10 | 2.41±0.62 |
组别 | 浓度(生药g%) | 结石浸泡前重量(mg) | 溶石率(%) | 浸泡液钙含量(mmol/L) |
受试药物 | 78.6 | 83.6±44.7 | 2.4±3.2 | 1.081±0.404* |
受试药物 | 20.6 | 84.8±41.8 | 2.0±2.6 | 0.323±0.156 |
结石通 | 100 | 83.9±41.2 | 1.7±2.2 | 1.176±0.743 |
去离子水 | - | 82.8±38.9 | 5.6±8.3 | 0.612±0.418 |
组别 | n | 剂量(/kg) | 15分钟扭体次数(X±S) | 抑制率(%) |
受试药物 | 10 | 2.60g | 18.6±9.86 | 18.6 |
受试药物 | 10 | 1.30g | 19.7±9.08 | 17.5 |
受试药物 | 10 | 0.65g | 19.2±10.1 | 16.2 |
罗通定 | 10 | 80mg | 5.6±3.09** | 76.5 |
常水 | 10 | 20ml | 22.9±15.5 |
组别 | 剂量(/kg) | 基础痛阈 | 药后痛阈值 | ||
1小时 | 2小时 | 3小时 | |||
受试药物 | 2.60g | 18.6±3.38 | 0.76±5.40 | -1.12±8.63 | 3.50±9.86* |
受试药物 | 1.30g | 18.5±3.32 | -3.76±4.67 | -2.78±3.46 | -2.65±2.68 |
受试药物 | 0.65g | 18.7±3.33 | -4.35±4.86 | -1.96±6.75 | -4.52±4.75 |
罗通定 | 80mg | 18.5±3.05 | 21.09±8.72** | 31.71±10.8** | 33.01±10.1** |
常水 | 20ml | 18.9±3.01 | -2.67±5.78 | -2.98±5.96 | -6.57±6.23 |
组别 | n | 剂量(/kg) | OD( X±S) | 抑制率(%) |
受试药物 | 10 | 2.60g | 0.081±0.030** | 49.8 |
受试药物 | 10 | 1.30g | 0.111±0.045* | 31.9 |
受试药物 | 10 | 0.65g | 0.131±0.056 | 23.4 |
泼尼松 | 10 | 20mg | 0.103±0.041* | 34.1 |
常水 | 10 | 20ml | 0.161±0.054 |
组别 | 剂量(/kg) | 正常值(ml) | 致炎后肿胀值(ml) | ||
2h | 4h | 6h | |||
受试药物 | 1.60g | 1.43±0.14 | 0.20±0.04 | 0.31±0.05* | 0.49±0.08 |
受试药物 | 0.80g | 1.41±0.16 | 0.22±0.03 | 0.32±0.05 | 0.52±0.13 |
受试药物 | 0.40g | 1.45±0.09 | 0.23±0.09 | 0.31±0.15 | 0.53±0.11 |
泼尼松 | 10mg | 1.46±0.08 | 0.15±0.08 | 0.28±0.06* | 0.35±0.08** |
常水 | 10ml | 1.45±0.10 | 0.24±0.14 | 0.45±0.12 | 0.59±0.18 |
组别 | N | 剂量(/kg) | 6小时排尿量(ml) | |
实际尿量 | 尿量/100g体重 | |||
受试药物 | 8 | 1.60g | 8.01±1.23* | 3.57±0.49* |
受试药物 | 8 | 0.80g | 7.43±1.26 | 3.18±0.58 |
受试药物 | 8 | 0.40g | 7.25±1.86 | 3.08±0.78 |
DHCT | 8 | 25mg | 9.18±1.78* | 3.89±0.68* |
常水 | 8 | 10ml | 5.98±1.87 | 2.67±0.78 |
组别 | 剂量(/kg) | n | 7天内死亡数 |
受试药物 | 1.60g | 10 | 9 |
受试药物 | 0.80g | 10 | 10 |
受试药物 | 0.40g | 10 | 10 |
诺氟沙星 | 600mg | 10 | 1 |
常水 | 20ml | 10 | 9 |
组别 | 剂量(/kg) | n | 7天内死亡数 |
受试药物 | 1.60g | 10 | 6 |
受试药物 | 0.80g | 10 | 9 |
受试药物 | 0.40g | 10 | 10 |
TMP+SMZ | 768mg | 10 | 0** |
常水 | 20ml | 10 | 9 |
菌种 | 菌号 | MIC(原药材g/L) |
大肠杆菌 | CMCC(B)44102 | 60.2 |
副大肠杆菌 | 临床株 | 60.3 |
变形杆菌 | CMCC(B)49102 | 13.9 |
金黄色葡萄球菌 | CMCC(B)26003 | 60.2 |
绿脓杆菌 | CMCC(B)10104 | 60.0 |
病种 | 例数 | 显效 | 有效 | 无效 | 总有效率 | |
例数 | % | |||||
尿石症 | 250 | 148 | 78 | 24 | 226 | 90.40 |
肾盂肾炎 | 10 | 8 | 1 | 1 | 9 | 90.00 |
下尿路感染 | 40 | 28 | 11 | 1 | 39 | 97.5 |
前列腺炎 | 50 | 28 | 20 | 2 | 48 | 96.0 |
乳糜血尿 | 3 | 1 | 1 | 1 | 2 | 66.67 |
合计 | 353 | 213 | 111 | 29 | 324 | 91.78 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610048680XA CN100443896C (zh) | 2006-09-18 | 2006-09-18 | 一种治疗泌尿系疾病的药物的质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610048680XA CN100443896C (zh) | 2006-09-18 | 2006-09-18 | 一种治疗泌尿系疾病的药物的质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1931292A true CN1931292A (zh) | 2007-03-21 |
CN100443896C CN100443896C (zh) | 2008-12-17 |
Family
ID=37877416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610048680XA Active CN100443896C (zh) | 2006-09-18 | 2006-09-18 | 一种治疗泌尿系疾病的药物的质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100443896C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412667A (zh) * | 2015-12-19 | 2016-03-23 | 林曦之 | 治疗癃闭的药酒及其制备方法 |
CN105475767A (zh) * | 2015-12-19 | 2016-04-13 | 林曦之 | 一种防治癃闭饮料及其制备方法 |
CN106442275A (zh) * | 2016-09-18 | 2017-02-22 | 中国人民武装警察部队总医院 | 一种定性检测乳糜的方法及试剂盒 |
CN107976509A (zh) * | 2017-11-01 | 2018-05-01 | 广西壮族自治区食品药品检验所 | 沙牛的薄层色谱鉴别方法 |
CN110201053A (zh) * | 2019-07-15 | 2019-09-06 | 河南白马健康产业有限公司 | 一种苗药前列腺贴及其制备方法 |
CN111467415A (zh) * | 2020-05-22 | 2020-07-31 | 沈阳东新药业有限公司 | 一种五淋化石胶囊的治疗用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091662A (zh) * | 1993-10-13 | 1994-09-07 | 梧州市人民制药厂 | 治疗尿石症和泌尿系感染的药物—五淋化石丹 |
-
2006
- 2006-09-18 CN CNB200610048680XA patent/CN100443896C/zh active Active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412667A (zh) * | 2015-12-19 | 2016-03-23 | 林曦之 | 治疗癃闭的药酒及其制备方法 |
CN105475767A (zh) * | 2015-12-19 | 2016-04-13 | 林曦之 | 一种防治癃闭饮料及其制备方法 |
CN106442275A (zh) * | 2016-09-18 | 2017-02-22 | 中国人民武装警察部队总医院 | 一种定性检测乳糜的方法及试剂盒 |
CN107976509A (zh) * | 2017-11-01 | 2018-05-01 | 广西壮族自治区食品药品检验所 | 沙牛的薄层色谱鉴别方法 |
CN107976509B (zh) * | 2017-11-01 | 2020-04-07 | 广西壮族自治区食品药品检验所 | 沙牛的薄层色谱鉴别方法 |
CN110201053A (zh) * | 2019-07-15 | 2019-09-06 | 河南白马健康产业有限公司 | 一种苗药前列腺贴及其制备方法 |
CN110201053B (zh) * | 2019-07-15 | 2021-07-09 | 河南白马健康产业有限公司 | 一种苗药前列腺贴及其制备方法 |
CN111467415A (zh) * | 2020-05-22 | 2020-07-31 | 沈阳东新药业有限公司 | 一种五淋化石胶囊的治疗用途 |
Also Published As
Publication number | Publication date |
---|---|
CN100443896C (zh) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103222988B (zh) | 一种美洲大蠊提取物及其制备方法和应用 | |
CN1931292A (zh) | 一种治疗泌尿系疾病的药物及质量控制方法 | |
CN104546992A (zh) | 杜仲叶提取物及其制备方法和用途 | |
CN109674778B (zh) | 脂类抗菌组合物、提取方法、检测方法和用途 | |
CN1977907A (zh) | 一种枇杷花提取物、含有该提取物的组合物及用途 | |
CN103623046A (zh) | 一种对化学性和酒精性肝损伤有辅助保护作用的组合物和制备方法及其在保健食品中的应用 | |
CN1057210C (zh) | 苦参芩连片及其制备方法 | |
CN1876073A (zh) | 治疗泌尿系统疾病的药物组合物 | |
CN102188494A (zh) | 一种纯中药治疗猪高热病的药物 | |
CN1275638C (zh) | 一种用于治疗盆腔炎症疾病的灌肠剂及其制备方法 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN1682969A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN1197612C (zh) | 治疗泌尿系统结石和尿路感染疾病的中药制剂及其制备方法 | |
CN101032571A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN101612204A (zh) | 猪链球菌耐药抑制剂 | |
CN105343229A (zh) | 一种防治畜禽大肠杆菌病的中药组合物及其制备方法 | |
CN1739682A (zh) | 一种用于腔道的裸花紫珠软胶囊及其制备方法 | |
CN101045103A (zh) | 一种治疗痛风的中兽药及其制备方法和用途 | |
CN101574355B (zh) | 一种兽用复方抗菌注射液及其制备方法 | |
CN101700367B (zh) | 治疗泌尿系统疾病的药物组合物 | |
CN101700370B (zh) | 治疗泌尿系统疾病的药物组合物的制备方法 | |
CN105983021A (zh) | 一种外用药物组合物、制备方法和用途 | |
CN1289110C (zh) | 治疗妇科疾病的胶囊制剂及其制备工艺 | |
CN107854526A (zh) | 一种治疗鸡大肠杆菌病的中药组合物及其制备方法和应用 | |
CN1299684C (zh) | 水产动物抗菌药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGXI WUZHOU SANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CAO YUN Effective date: 20070511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070511 Address after: 543002, two, Fumin road 28, butterfly mountain area, the Guangxi Zhuang Autonomous Region, Wuzhou Applicant after: Guangxi Wuzhou Sanhe Pharmaceutical Co.,Ltd. Address before: 510630 Guangdong city of Guangzhou province Guangzhou Shipai China Normal University high school room 1401 Applicant before: Cao Yun |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Two the Guangxi Zhuang Autonomous Region Wuzhou Fumin road 543002 No. 28 Patentee after: GUANGXI WUZHOU 3HE PHARMACEUTICAL CO., LTD. Address before: 543002, two, Fumin road 28, butterfly mountain area, the Guangxi Zhuang Autonomous Region, Wuzhou Patentee before: Guangxi Wuzhou Sanhe Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A quality control method of drugs for treating urinary diseases Effective date of registration: 20220106 Granted publication date: 20081217 Pledgee: Bank of Guilin Co.,Ltd. Wuzhou branch Pledgor: GUANGXI WUZHOU SANHE PHARMACEUTICAL CO.,LTD. Registration number: Y2022450000002 |